JP3204348B2 - Arteriosclerosis inhibitor and food or medicine containing it - Google Patents
Arteriosclerosis inhibitor and food or medicine containing itInfo
- Publication number
- JP3204348B2 JP3204348B2 JP22798293A JP22798293A JP3204348B2 JP 3204348 B2 JP3204348 B2 JP 3204348B2 JP 22798293 A JP22798293 A JP 22798293A JP 22798293 A JP22798293 A JP 22798293A JP 3204348 B2 JP3204348 B2 JP 3204348B2
- Authority
- JP
- Japan
- Prior art keywords
- arteriosclerosis
- arteriosclerosis inhibitor
- inhibitor
- licorice
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【０００１】[0001]
【産業上の利用分野】本発明は動脈硬化抑制剤、及びこ
れを含む食品、又はこれを含む循環器疾患治療用の医薬
組成物に関する。The present invention relates to an arteriosclerosis inhibitor, a food containing the same, and a pharmaceutical composition containing the same for treating cardiovascular diseases.
【０００２】[0002]
【従来の技術】近年、食生活の欧米化が進むにつれて、
国民一人あたりの脂肪摂取量も増加し続けており、中で
も、若年層に於ける総脂肪摂取量の増加と全年齢層に於
ける動物性脂肪摂取量の増加が著しい。このため、過度
に摂取された脂肪によって血中脂質のバランスが崩れた
り、高脂血症が引き起こされたりする。これらが引き金
となって動脈硬化をはじめとする循環器系の成人病にか
かる人が多く、また、循環器系成人病の若年化現象を招
き、大きな社会問題の１つとなっている。2. Description of the Related Art In recent years, as eating habits have become westernized,
The per capita fat intake continues to increase, with a marked increase in total fat intake among young people and animal fat intake among all ages. For this reason, excessively ingested fat may cause an imbalance in blood lipids or hyperlipidemia. These trigger many people to suffer from adult diseases of the circulatory system such as arteriosclerosis, and also cause a younger phenomenon of adult diseases of the circulatory system, which is one of the major social problems.
【０００３】このような循環器系成人病の増加を防ぐた
めには、動脈硬化の原因となる高脂血症等の血中脂質の
バランスを改善することが必要であり、その方法として
は、従来より、リノール酸等の多価不飽和脂肪酸を摂取
する方法や、クロロフィブレートやニコチン酸等を用い
る方法が知られていた。[0003] In order to prevent such an increase in cardiovascular adult diseases, it is necessary to improve the balance of blood lipids such as hyperlipidemia which causes arteriosclerosis. Thus, a method of ingesting a polyunsaturated fatty acid such as linoleic acid and a method of using chlorofibrate, nicotinic acid, and the like have been known.
【０００４】しかしながら、多価不飽和脂肪酸の摂取は
長期連用が必要な上、過剰摂取に問題があり、クロロフ
ィブレートは筋けいれん等の副作用があり、またニコチ
ン酸にも全身紅潮や胃腸障害等の副作用が有るといった
問題があった。However, ingestion of polyunsaturated fatty acids requires long-term continuous use, and there is a problem of excessive intake. Chlorofibrate has side effects such as muscle spasm. There was a problem that there were side effects.
【０００５】[0005]
【発明が解決しようとする課題】従って、本発明は血中
脂質量のバランスを改善する作用を有し、動脈硬化を抑
制する効果に優れ、且つ、安全性の高い動脈硬化抑制剤
と、これを含む食品又は循環器疾患治療用の医薬組成物
を提供することを目的とする。Accordingly, the present invention provides a highly safe arteriosclerosis inhibitor which has an effect of improving the balance of blood lipid content, has an excellent effect of suppressing arteriosclerosis, and is highly safe. It is intended to provide a food or a pharmaceutical composition for treating a circulatory disease containing the same.
【０００６】[0006]
【課題を解決するための手段】上記実状に鑑み、本発明
者らは、古来より用いられてきており、その使用につい
て、安全であると思われる、漢方生薬を選択し、その抽
出物を、動脈硬化抑制作用を指標として広くスクリーニ
ングした結果、甘草の抽出物に優れた動脈硬化抑制作用
が有るのを見いだし発明を完成させた。Means for Solving the Problems In view of the above situation, the present inventors have selected a Chinese herbal medicine which has been used since ancient times and is considered safe for its use, As a result of extensive screening using the arteriosclerosis inhibitory action as an index, the inventors found that an extract of licorice had an excellent arteriosclerosis inhibitory action and completed the invention.
【０００７】従って、本発明は甘草の抽出物からなる動
脈硬化抑制剤に関する。Accordingly, the present invention relates to an arteriosclerosis inhibitor comprising an extract of licorice.
【０００８】また、本発明は上記動脈硬化抑制剤を含有
する食品に関する。[0008] The present invention also relates to a food containing the above-mentioned arteriosclerosis inhibitor.
【０００９】更に、本発明は上記動脈硬化抑制剤を含有
する循環器疾患治療用の医薬組成物に関する。Further, the present invention relates to a pharmaceutical composition for treating cardiovascular diseases, comprising the above-mentioned arteriosclerosis inhibitor.
【００１０】ところで、本発明で用いる甘草であるが、
これは豆科グリキリザ属の植物の総称で、洋甘草（G.gl
abra L.）、ナンキンカンゾウ（G.glabra L.var glandu
rifera Regel et Herder）、ウラルカンゾウ（G.uralen
sis Fisch.et DC）、シナカンゾウ（G.echinata L.）、
イヌカンゾウ（G.pallidiflora Maxim）、脹果甘草（G.
infrata BAT）などを指し、このものは漢方生薬として
古くから、中国でも、又、日本に於いても広く用いられ
てきた。その漢方に於ける薬効は鎮痛、解熱、鎮咳等で
あり、血中脂質のバランスの改善や動脈硬化抑制作用に
ついては全く知られていなかった。By the way, the licorice used in the present invention,
This is a generic term for plants belonging to the genus Glycirridae,
abra L.), Nankin licorice (G.glabra L.var glandu)
rifera Regel et Herder, G.uralen
sis Fisch.et DC), Chinese elephant (G. echinata L.),
Dog liquorice (G. pallidiflora Maxim), Maruti licorice (G.
infrata BAT), which has been widely used as a herbal medicine in China and in Japan since ancient times. Its medicinal properties in Chinese medicine are analgesia, antipyretic, antitussive, etc., and no improvement in blood lipid balance or arteriosclerosis inhibitory action was known at all.
【００１１】上記甘草は、血中脂質量のバランスを改善
する作用を有する物質を含んでおり、粉砕した全草を用
いることも可能であるが、抽出により前記成分を含む抽
出物を取り出して、本発明の動脈硬化抑制剤の有効成分
として用いることが好ましい。又、用いる植物の部位と
しては全草でも可能であるが、薬効成分の豊富な根や根
茎が好ましい。本発明に於いて抽出物とは、このような
粉砕物及び抽出物、更に後述する分画物、又はこれらの
濃縮物から選ばれる１種または２種以上を言う。[0011] The licorice contains a substance having an effect of improving the balance of the amount of lipids in blood, and it is possible to use whole pulverized plants. It is preferable to use it as an active ingredient of the arteriosclerosis inhibitor of the present invention. The whole plant can be used as a plant part to be used, but a root or rhizome rich in medicinal ingredients is preferable. In the present invention, the extract refers to one or more selected from such a pulverized product and an extract, a fractionated product described below, or a concentrate thereof.
【００１２】甘草の抽出処理は、連続式、バッチ式等の
方法で、常法により冷浸または温浸にて任意の時間行
う。例えば、甘草の根及び根茎を乾燥した後、細切し、
抽出溶媒に、室温で１〜３日間、または抽出溶媒の沸騰
温度で１〜５時間浸漬すれば良い。この時、用いる抽出
溶媒としては、水及びアルコール類、アセトン類等の極
性有機溶媒が良く、これらを単独で用いても２種以上を
混合して用いても良い。その後、必要に応じて不溶物を
ろ過により除去したり、減圧または限外ろ過により濃縮
し、溶媒を乾固させても良い。好ましいものは、温湯抽
出したものをろ過した後凍結乾燥したものであり、この
ものは褐色の吸湿性を有するアモルファスである。The licorice extraction process is carried out by a conventional method, such as a continuous method or a batch method, by cold or hot digestion for an arbitrary time. For example, after drying the roots and rhizomes of licorice, shred,
It may be immersed in the extraction solvent at room temperature for 1 to 3 days or at the boiling temperature of the extraction solvent for 1 to 5 hours. At this time, as the extraction solvent to be used, water and polar organic solvents such as alcohols and acetones are preferable, and these may be used alone or in combination of two or more. Thereafter, if necessary, the solvent may be removed by filtration, or concentrated by reduced pressure or ultrafiltration to dry the solvent. A preferred product is a product obtained by extracting the hot water, followed by filtration and freeze-drying. This product is a brown hygroscopic amorphous material.
【００１３】かくして得られた抽出物を製剤化に用いて
も良いが、更にこの抽出物のうち血中脂質量のバランス
を改善する作用を有する成分を高濃度に含有する分画物
を使用しても良い。分画物を得るためには、上記抽出物
から求める作用の少ない極性が著しく高い部分を除去す
るのが好ましく、その方法としては、液液抽出法、吸着
カラムクロマトグラフィー法、分配カラムクロマトグラ
フィー法、ＧＰＣカラムクロマトグラフィー法等が例示
できる。このうち、多孔性スチレンージビニルベンゼン
コポリマーを担体として用いた分配カラムクロマトグラ
フィー法が最も手軽で好ましい。[0013] The extract thus obtained may be used in the preparation of a pharmaceutical preparation, and a fraction containing a high concentration of a component having an effect of improving the balance of blood lipid content in the extract may be used. May be. In order to obtain a fraction, it is preferable to remove a portion having a small effect and a remarkably high polarity from the extract, and the method includes a liquid-liquid extraction method, an adsorption column chromatography method, and a partition column chromatography method. , GPC column chromatography and the like. Among them, the distribution column chromatography method using a porous styrene divinylbenzene copolymer as a carrier is the simplest and preferable.
【００１４】多孔性スチレンージビニルベンゼンコポリ
マーを用いて分画を得るには、例えば次のように行えば
良い。即ち、アンバーライトＸＡＤー２（オルガノ
（株）製）に上記抽出物を精製水に溶かしたものを通
し、精製水で充分洗浄した後、アルコール類等の極性有
機溶媒で溶出させれば良い。また、バッチ法で行うこと
もできるし、予め、ノルマルヘキサンや石油エーテルで
脱脂処理を行っておいても良い。To obtain a fraction using a porous styrene-divinylbenzene copolymer, for example, the following procedure may be performed. That is, a solution obtained by dissolving the above extract in purified water is passed through Amberlite XAD-2 (manufactured by Organo Corporation), washed sufficiently with purified water, and eluted with a polar organic solvent such as alcohol. Further, it may be carried out by a batch method, or may be subjected to a degreasing treatment with normal hexane or petroleum ether in advance.
【００１５】かくして得られた抽出物及び分画物はとも
に動脈硬化抑制剤として用いることができる。この動脈
硬化抑制剤は、そのまま製剤とすることもできるし、各
種基剤に配合して製剤としても良い。Both the extract and the fraction thus obtained can be used as an arteriosclerosis inhibitor. The arteriosclerosis inhibitor may be used as a preparation as it is, or may be mixed with various bases to prepare a preparation.
【００１６】配合量や基剤の種類は特に限定されるもの
ではなく、剤形に合わせて、適宜、設定すれば良く、例
えば、医薬品としては、錠剤、散剤、顆粒剤、カプセル
剤、坐剤、注射剤、液剤等が例示でき、これらは増量
剤、賦形剤、滑沢剤、崩壊剤、結合剤、矯味矯臭剤等と
共に通常の方法に従って剤形化すれば良い。The compounding amount and the type of base are not particularly limited, and may be appropriately set according to the dosage form. For example, as pharmaceuticals, tablets, powders, granules, capsules, suppositories And injections, liquid preparations, etc., which may be formulated in a usual manner together with bulking agents, excipients, lubricants, disintegrants, binders, flavoring agents and the like.
【００１７】又、食品としては、一般食品として、種々
の食品原料に抽出物の所要量を加え、通常の製造方法に
より加工することにより、また、健康食品、機能性食品
として植物や抽出物、分画物をそのまま、或いは食べ易
い状態にして使用することができる。As foods, general foods can be prepared by adding the required amount of extract to various food ingredients and processing them by a usual production method. The fraction can be used as it is or in a state where it is easy to eat.
【００１８】これらの組成物に於ける、上記動脈硬化抑
制剤の１日あたりの投与量は、症状、身長、体重、年齢
等により異なるが、成人１人あたり１〜２０００ｍｇ／
Ｋｇ、好ましくは３〜１００ｍｇ／Ｋｇを１回ないし数
回に分けて投与するのがよい。The daily dose of the above-mentioned arteriosclerosis inhibitor in these compositions varies depending on symptoms, height, weight, age, etc., but it is 1 to 2000 mg / adult per adult.
Kg, preferably 3 to 100 mg / Kg, may be administered once or several times.
【００１９】また、本発明の動脈硬化抑制剤の安全性
は、甘草が古来より広く漢方生薬として用いられてきた
実績より、優れているのは明白である。It is clear that the safety of the arteriosclerosis inhibitor of the present invention is superior to that of licorice, which has been widely used as a Chinese herbal medicine since ancient times.
【００２０】[0020]
【実施例】以下に、実施例を挙げて更に詳しく本発明に
ついて説明するが、本発明がこれら実施例に限定を受け
ないことは言うまでもない。EXAMPLES Hereinafter, the present invention will be described in more detail with reference to Examples, but it goes without saying that the present invention is not limited to these Examples.
【００２１】実施例１． 製造例１．洋甘草の根および根茎を５〜１０ｍｍの長さ
に細切したもの１００ｇに、精製水１０００ｍｌを加え
て１０５℃にて３時間還流して、抽出した。冷却後、ろ
過してろ液を取り、減圧濃縮後凍結乾燥し２１．９グラ
ムの動脈硬化抑制剤を褐色アモルファスとして得た。Embodiment 1 Production Example 1. 1000 ml of purified water was added to 100 g of the licorice root and rhizome chopped to a length of 5 to 10 mm, and the mixture was extracted by refluxing at 105 ° C. for 3 hours. After cooling, the filtrate was collected by filtration, concentrated under reduced pressure, and freeze-dried to obtain 21.9 g of an arteriosclerosis inhibitor as a brown amorphous.
【００２２】実施例２． 製造例２．製造例１の動脈硬化抑制剤６ｇを３０ｍｌの
精製水に溶解させ、アンバーライトＸＡＤー２を充填し
たカラムに通し、更に５００ｍｌの精製水を流し洗浄し
た。これに９９．５％エタノール５００ｍｌで溶出さ
せ、減圧濃縮して２．０ｇの動脈硬化抑制剤を得た。Embodiment 2 FIG. Production Example 2. 6 g of the arteriosclerosis inhibitor of Production Example 1 was dissolved in 30 ml of purified water, passed through a column filled with Amberlite XAD-2, and further washed with 500 ml of purified water. This was eluted with 500 ml of 99.5% ethanol, and concentrated under reduced pressure to obtain 2.0 g of an arteriosclerosis inhibitor.
【００２３】実施例３． 製造例３．ウラルカンゾウの根及び根茎を５〜１０ｍｍ
の長さに細切したもの１００ｇに精製水１０００ｍｌを
加えて１０５℃にて３時間還流して、抽出した。冷却
後、ろ過してろ液を取り、減圧濃縮後凍結乾燥して１
７．８ｇの動脈硬化抑制剤を褐色アモルファスとして得
た。Embodiment 3 FIG. Production Example 3 5-10 mm for roots and rhizomes of Uralkan elephant
1000 g of purified water was added to 100 g of the mixture cut into lengths, and the mixture was refluxed at 105 ° C. for 3 hours and extracted. After cooling, the filtrate was collected by filtration, concentrated under reduced pressure, lyophilized, and dried.
7.8 g of arteriosclerosis inhibitor was obtained as brown amorphous.
【００２４】実施例４． 製造例４．ナンキンカンゾウの根及び根茎を５〜１０ｍ
ｍの長さに細切したもの１００ｇに精製水５００ｍｌと
エタノール５００ｍｌを加えて１０５℃で３時間還流し
て抽出した。冷却後、ろ過してろ液を取り、減圧濃縮後
凍結乾燥して１８．４ｇの動脈硬化抑制剤を得た。Embodiment 4 FIG. Production Example 4. 5-10 m of roots and rhizomes of licorice
500 g of purified water and 500 ml of ethanol were added to 100 g of the m-sized pieces, and the mixture was extracted by refluxing at 105 ° C. for 3 hours. After cooling, the filtrate was collected by filtration, concentrated under reduced pressure, and freeze-dried to obtain 18.4 g of an arteriosclerosis inhibitor.
【００２５】実施例５． 急性毒性毒性試験 体重１５〜２５ｇのｄｄｙ系マウス１群１０匹を用いて
経口投与での急性毒性試験を行った。試料は実施例１〜
４の動脈硬化抑制剤を用いた。それぞれの試料を３０％
生理食塩水溶液にし、１２ｇ／Ｋｇ経口投与し、７２時
間後に生死の判定を行った。何れの群に於いても死亡例
を認めなかった。これより本発明の動脈硬化抑制剤の安
全性が高いことが明らかである。Embodiment 5 FIG. Acute toxicity toxicity test An acute toxicity test by oral administration was performed using ten ddy mice weighing 15 to 25 g per group. The samples were from Examples 1 to
The arteriosclerosis inhibitor of No. 4 was used. 30% of each sample
It was made into a physiological saline solution and orally administered at a dose of 12 g / Kg. No deaths were found in any of the groups. This clearly shows that the arteriosclerosis inhibitor of the present invention has high safety.
【００２６】実施例６． 動脈硬化抑制作用の評価１ 実施例１、３、４の動脈硬化抑制剤について動脈硬化抑
制効果に付いて、評価を行った。即ち、１群１０匹の５
週齢ＩＣＲマウスを日本クレア製ＣＥー２（８０％）及
びセルロースパウダー（２０％）の混合固形飼料と水を
自由摂取させて４週間予飼育した。その後、ブランク群
はそのまま混合固形飼料と水を、コントロール群、実施
例１投与群、実施例３投与群、実施例４投与群はＣＥー
２（８０％）及びラード（２０％）の高脂肪混合固形飼
料と水を自由摂取させながら、同時にコントロール群と
ブランク群には１重量％カルボキシメチルセルロースナ
トリウム水溶液を、実施例１投与群、実施例３投与群、
実施例４投与群には、それぞれ、実施例１、３、４の動
脈硬化抑制剤を１０重量％含有する１重量％カルボキシ
メチルセルロースナトリウム水溶液を０．５ｍｌ／匹／
１日の投与量で２週間経口投与した。投与終了後、すべ
てのマウスを１６時間絶食させ、採血を行った。得られ
た血液より、常法により血清を分離し、酵素法により総
コレステロール量を、ヘパリンーＭｎ沈澱酵素法により
ＨＤＬコレステロール量を測定した。総コレステロール
量よりＨＤＬコレステロール量を減じ、これをＨＤＬコ
レステロール量で除した値を動脈硬化指数とし、この値
を用いて動脈硬化抑制作用の指標とした。結果を表１に
示す。なお、ここで＊は５％未満の危険率で、＊＊は１
％未満の危険率でコントロール群と有意差が有ったこと
を示す。これより、本発明の動脈硬化抑制剤は優れた動
脈硬化抑制作用を有することが判る。Embodiment 6 FIG. Evaluation of Arteriosclerosis Inhibiting Action 1 The arteriosclerosis inhibitor of Examples 1, 3, and 4 was evaluated for its arteriosclerosis inhibitory effect. That is, 5 of 10 animals per group
Week-old ICR mice were pre-fed for 4 weeks with free access to water and a mixed solid feed of CE-2 (80%) and cellulose powder (20%) manufactured by CLEA Japan. Thereafter, the blank group received the mixed solid feed and water, and the control group, the administration group of Example 1, the administration group of Example 3, and the administration group of Example 4 exhibited CE-2 (80%) and lard (20%) high fat. A 1% by weight aqueous solution of sodium carboxymethylcellulose was added to the control group and the blank group at the same time while the mixed solid feed and water were freely ingested.
In the administration group of Example 4, 0.5 ml / mouse of a 1% by weight aqueous solution of sodium carboxymethylcellulose containing 10% by weight of the arteriosclerosis inhibitor of Examples 1, 3, and 4 was used.
Oral administration was performed at a daily dose for 2 weeks. After completion of the administration, all mice were fasted for 16 hours and blood was collected. Serum was separated from the obtained blood by an ordinary method, and the total cholesterol amount was measured by an enzyme method, and the HDL cholesterol amount was measured by a heparin-Mn precipitation enzyme method. The value obtained by subtracting the HDL cholesterol amount from the total cholesterol amount and dividing the HDL cholesterol amount by the HDL cholesterol amount was used as an arteriosclerosis index, and this value was used as an index of the arteriosclerosis inhibitory action. Table 1 shows the results. Note that * is a risk factor of less than 5% and ** is 1
Indicates that there was a significant difference from the control group at a risk rate of less than 10%. This indicates that the arteriosclerosis inhibitor of the present invention has an excellent arteriosclerosis inhibitory action.
【００２７】[0027]
【表１】 [Table 1]
【００２８】実施例７． 動脈硬化抑制作用の評価２ 実施例２の動脈硬化抑制剤についても実施例６と同様に
動脈硬化抑制作用について評価を行った。結果を表２に
示す。これより本発明の動脈硬化抑制剤が優れた動脈硬
化抑制作用を有しているのが明らかである。Embodiment 7 FIG. Evaluation 2 of Arteriosclerosis Inhibitory Effect The arteriosclerosis inhibitor of Example 2 was evaluated in the same manner as in Example 6 for its arteriosclerosis inhibitory effect. Table 2 shows the results. This clearly shows that the arteriosclerosis inhibitor of the present invention has an excellent arteriosclerosis inhibitory action.
【００２９】[0029]
【表２】 [Table 2]
【００３０】実施例８． キャンディーへの配合例１ 下記の（Ａ）成分を１５０℃で加熱溶解し、１２０℃に
冷却後、（Ｂ）成分を添加、攪はん後均一としたものを
成型し、冷却してキャンディーを得た。 （Ａ） 砂糖 ５８ 水飴 ３０ （Ｂ） クエン酸 １ 実施例１の動脈硬化抑制剤 １０ 香料 １Embodiment 8 FIG. Formulation Example 1 to Candy The following component (A) is heated and melted at 150 ° C., cooled to 120 ° C., added with component (B), stirred to form a uniform product, and cooled to obtain a candy. Obtained. (A) sugar 58 syrup 30 (B) citric acid 1 arteriosclerosis inhibitor of Example 1 10 fragrance 1
【００３１】実施例９． キャンディーへの配合例２ 下記の（Ａ）成分を１５０℃で加熱溶解し、１２０℃に
冷却後、（Ｂ）成分を添加、攪はん後均一としたものを
成型し、冷却してキャンディーを得た。 （Ａ） 砂糖 ６７ 水飴 ３０ （Ｂ） クエン酸 １ 実施例２の動脈硬化抑制剤 １ 香料 １Embodiment 9 FIG. Formulation Example 2 to Candy The following component (A) is heated and dissolved at 150 ° C., cooled to 120 ° C., and the component (B) is added. Obtained. (A) sugar 67 syrup 30 (B) citric acid 1 arteriosclerosis inhibitor of Example 2 1 fragrance 1
【００３２】実施例１０． グミへの配合例１．下記の（Ａ）成分を１１０℃で加熱
溶解し、別途膨潤溶解させた（Ｂ）成分を添加し、更に
（Ｃ）成分を添加し、型に流し込み、１昼夜放置後型か
らはずしてグミを得た。 （Ａ） 砂糖 ４０ 水飴 ４５ （Ｂ） ゼラチン ８ （Ｃ） クエン酸 ２ 実施例３の動脈硬化抑制剤 ５Embodiment 10 FIG. Example of formulation to gummy The following component (A) is heated and dissolved at 110 ° C., and the separately swelled and dissolved component (B) is added. The component (C) is further added and poured into a mold. Obtained. (A) sugar 40 starch syrup 45 (B) gelatin 8 (C) citric acid 2 arteriosclerosis inhibitor of Example 3 5
【００３３】実施例１１． グミへの配合例２．下記の（Ａ）成分を１１０℃で加熱
溶解し、別途膨潤溶解させた（Ｂ）成分を添加し、更に
（Ｃ）成分を添加し、型に流し込み、１昼夜放置後型か
らはずしてグミを得た。 （Ａ） 砂糖 ４０ 水飴 ４５ （Ｂ） ゼラチン ８ （Ｃ） クエン酸 ２ 実施例４の動脈硬化抑制剤 ５Embodiment 11 FIG. Example of formulation to gummies 2. The following component (A) is heated and dissolved at 110 ° C., and the separately swelled and dissolved component (B) is added. The component (C) is further added and poured into a mold. Obtained. (A) sugar 40 starch syrup 45 (B) gelatin 8 (C) citric acid 2 arteriosclerosis inhibitor of Example 4 5
【００３４】実施例１２． カプセル剤 下記の（Ａ）成分を均一に混合攪はんし、これに（Ｂ）
成分を加えてニーダーにより充分に混練した。これをカ
プセル充填機によりカプセル化しカプセル剤を作成し
た。 （Ａ） スクワレン １５ リノレン酸トリグリセライド １５ 小麦胚芽油 １０ 精製イワシ油 ２０ αーｄートコフェロール ０．２ （Ｂ） 脱脂大豆粉末 ３９．８ 実施例２の動脈硬化抑制剤 １０Embodiment 12 FIG. Capsule The following component (A) is uniformly mixed and stirred, and then mixed with (B)
The ingredients were added and kneaded well with a kneader. This was encapsulated by a capsule filling machine to prepare a capsule. (A) squalene 15 linolenic triglyceride 15 wheat germ oil 10 purified sardine oil 20 α-d-tocopherol 0.2 (B) defatted soybean powder 39.8 Arteriosclerosis inhibitor 10 of Example 2
【００３５】実施例１３． 錠剤 下記成分を均一に混合し、流動層造粒法により造粒し、
乾燥させた。これを打錠機で打錠し錠剤を得た。 デキストリン １５ 乳糖 ５ パラチノース １５ バレイショデンプン ４０ ステアリン酸マグネシウム ５ 実施例３の動脈硬化抑制剤 ２０Embodiment 13 FIG. Tablets The following ingredients are mixed uniformly and granulated by a fluid bed granulation method.
Let dry. This was tableted with a tableting machine to obtain tablets. Dextrin 15 Lactose 5 Palatinose 15 Potato starch 40 Magnesium stearate 5 Arteriosclerosis inhibitor of Example 3 20
【００３６】実施例１４． 顆粒剤 下記（Ａ）成分をグラッド造粒機に入れ、（Ｂ）成分の
５％水溶液を滴下しながら造粒し、４０℃で乾燥させ、
整粒し顆粒剤を得た。 （Ａ） 乳糖 ６７．５ コーンスターチ １０ 実施例４の動脈硬化抑制剤 ２０ （Ｂ） ヒドロキシプロピルセルロース ２．５Embodiment 14 FIG. Granules The following component (A) is placed in a grading machine and granulated while dropping a 5% aqueous solution of component (B), and dried at 40 ° C.
The granules were sized to obtain granules. (A) Lactose 67.5 Corn starch 10 Arteriosclerosis inhibitor of Example 4 20 (B) Hydroxypropylcellulose 2.5
【００３７】[0037]
【発明の効果】本発明の動脈効果抑制剤は安全性が高い
上に優れた動脈効果抑制作用を有するので、循環器の疾
病の予防と治療にたいへん有益である。EFFECTS OF THE INVENTION The arterial effect inhibitor of the present invention is highly useful in preventing and treating cardiovascular diseases, because it is highly safe and has an excellent inhibitory effect on arterial effect.
フロントページの続き (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 35/78 A23G 3/00 101 A23L 1/30 ＢＩＯＳＩＳ（ＤＩＡＬＯＧ) ＣＡ（ＳＴＮ)Continued on the front page (58) Fields surveyed (Int. Cl. 7 , DB name) A61K 35/78 A23G 3/00 101 A23L 1/30 BIOSIS (DIALOG) CA (STN)
Claims (3)
からなる動脈硬化抑制剤。1. An arteriosclerosis inhibitor comprising water and / or a polar organic solvent extract of licorice.
る経口用組成物。2. An oral composition comprising the arteriosclerosis inhibitor according to claim 1.
する循環器疾患治療用の医薬組成物。3. A pharmaceutical composition for treating cardiovascular disease, comprising the arteriosclerosis inhibitor according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22798293A JP3204348B2 (en) | 1993-08-20 | 1993-08-20 | Arteriosclerosis inhibitor and food or medicine containing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22798293A JP3204348B2 (en) | 1993-08-20 | 1993-08-20 | Arteriosclerosis inhibitor and food or medicine containing it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0753393A JPH0753393A (en) | 1995-02-28 |
| JP3204348B2 true JP3204348B2 (en) | 2001-09-04 |
Family
ID=16869311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22798293A Expired - Fee Related JP3204348B2 (en) | 1993-08-20 | 1993-08-20 | Arteriosclerosis inhibitor and food or medicine containing it |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3204348B2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100385524B1 (en) * | 2000-07-26 | 2003-05-27 | 정태호 | Herb composition for prevention of atherosclerosis |
| TWI329516B (en) * | 2000-12-12 | 2010-09-01 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity |
| KR20040030376A (en) * | 2002-10-02 | 2004-04-09 | 천연제약 주식회사 | Pharmaceutical composition for treatment of thrombosis |
| KR100970826B1 (en) * | 2008-06-30 | 2010-07-16 | 원광대학교산학협력단 | Composition comprising mixed herbal extract for preventing and treating vascular disease |
| JP6050572B2 (en) * | 2011-08-10 | 2016-12-21 | ロート製薬株式会社 | Elastic fiber formation promoter |
| JP6050573B2 (en) * | 2011-08-10 | 2016-12-21 | ロート製薬株式会社 | LTBP-4 production promoter |
| KR101461588B1 (en) * | 2012-09-26 | 2014-11-19 | 한국 한의학 연구원 | Pharmaceutical composition for preventing or treating arteriosclerosis |
-
1993
- 1993-08-20 JP JP22798293A patent/JP3204348B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 治療学，ｖｏｌ．１４，ｎｏ．１，ｐ１２７−１３４，１９８５ |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0753393A (en) | 1995-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002179586A (en) | Lipase inhibitor | |
| KR20190132420A (en) | Herbal composition | |
| JP3204348B2 (en) | Arteriosclerosis inhibitor and food or medicine containing it | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| JPH07238027A (en) | Arterioscelerosis inhibitor and food or medicine containing the same | |
| KR100979459B1 (en) | Tetracera scandens extracts and 4H-chromen-4-one derivatives isolated therefrom increasing glucose uptake in differentiated L6 muscle cells | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JP3512118B2 (en) | Blood lipid improver | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
| JPH07238026A (en) | Arteriosclerosis inhibitor and food or medicine containing the same | |
| CN111035620A (en) | Auxiliary material composition, phytosterol compound nutrient chewable tablet and preparation method thereof | |
| JP3183758B2 (en) | Blood neutral fat ameliorating agent, method for producing the same, and composition containing the same | |
| CN111346194A (en) | Application of heart-nourishing Dawayimicke preparation | |
| JP4712928B2 (en) | Chronic hepatitis inhibitor | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| TWI440465B (en) | Herbal extract mixture for reducing blood lipid and a combination thereof | |
| JPS60260520A (en) | Drug composition | |
| JP4454069B2 (en) | Chronic hepatitis inhibitor | |
| CN101816708A (en) | Treat rheumatismal Chinese medicine composition and preparation method thereof | |
| JP4712927B2 (en) | Chronic hepatitis inhibitor | |
| JPH03190820A (en) | Cerebral function improver | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| JP4406503B2 (en) | New liver disorder inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |